AstraZeneca is resuming clinical trials in the U.K. of its COVID-19 vaccine after getting approval from safety watchdogs.
The company said on Saturday that the late-stage trials were allowed to resume after an illness in a study subject was identified.
Even though it was just one illness it cast doubts on early-rollout of the vaccine, which some in President Donald Trump’s administration has said could come by November.
“On 6 September, the standard review process triggered a voluntary pause to vaccination across all global trials to allow review of safety data by independent committees, and international regulators,” AstraZeneca said in a statement.
The patient involved had reportedly suffered from neurological symptoms associated with a rare spinal inflammatory disorder called transverse myelitis.
COVID-19 has killed more than 900,000 people across the world.
FingerLakes1.com is the region’s leading all-digital news publication. The company was founded in 1998 and has been keeping residents informed for more than two decades. Have a lead? Send it to [email protected].